You are here: Home > Prescription(RX) Drugs > A > Actimmune (Intermune, Inc.)

Manufacturer:Intermune, Inc.
Category:Prescription Marketed Drugs

ACTIMMUNE® (Interferon gamma-1b)

ACTIMMUNE  - interferon gamma-1b injection, solution 
InterMune, Inc.


ACTIMMUNE® (Interferon gamma-1b)


ACTIMMUNE®  (Interferon gamma-1b), a biologic response modifier, is a single-chain polypeptide containing 140 amino acids. Production of ACTIMMUNE  is achieved by fermentation of a genetically engineered Escherichia coli  bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. ACTIMMUNE  is a highly purified sterile solution consisting of non-covalent dimers of two identical 16,465 dalton monomers; with a specific activity of 20 million International Units (IU)/mg (2x106 IU per 0.5 mL) which is equivalent to 30 million units/mg.

ACTIMMUNE  is a sterile, clear, colorless solution filled in a single-use vial for subcutaneous injection. Each 0.5 mL of ACTIMMUNE  contains: 100 mcg (2 million IU) of Interferon gamma-1b formulated in 20 mg mannitol, 0.36 mg sodium succinate, 0.05 mg polysorbate 20 and Sterile Water for Injection. Note that the above activity is expressed in International Units (1 million IU/50mcg). This is equivalent to what was previously expressed as units (1.5 million U/50mcg).



Interferons bind to specific cell surface receptors and initiate a sequence of intracellular events that lead to the transcription of interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind to the alpha/beta receptor. Interferon-gamma binds to a different cell surface receptor and is classified as Type 2 interferon. Specific effects of interferon-gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), activation of natural killer (NK) cells, and the expression of Fc receptors and major histocompatibility antigens.

Chronic Granulomatous Disease (CGD) is an inherited disorder of leukocyte function caused by defects in the enzyme complex responsible for phagocyte superoxide generation. ACTIMMUNE  does not increase phagocyte superoxide production even in treatment responders.1

In severe, malignant osteopetrosis (an inherited disorder characterized by an osteoclast defect, leading to bone overgrowth, and by deficient phagocyte oxidative metabolism), a treatment-related enhancement of superoxide production by phagocytes was observed. ACTIMMUNE  was found to enhance osteoclast function in vivo.2-4

In both disorders, the exact mechanism(s) by which ACTIMMUNE  has a treatment effect has not been established. Changes in superoxide levels during ACTIMMUNE  therapy do not predict efficacy and should not be used to assess patient response to therapy.


The intravenous, intramuscular, and subcutaneous pharmacokinetics of ACTIMMUNE  have been investigated in 24 healthy male subjects following single-dose administration of 100 mcg/m2. ACTIMMUNE  is rapidly cleared after intravenous administration (1.4 liters/minute) and slowly absorbed after intramuscular or subcutaneous injection. After intramuscular or subcutaneous injection, the apparent fraction of dose absorbed was greater than 89%. The mean elimination half-life after intravenous administration of 100 mcg/m2 in healthy male subjects was 38 minutes. The mean elimination half-lives for intramuscular and subcutaneous dosing with 100 mcg/m2 were 2.9 and 5.9 hours, respectively. Peak plasma concentrations, determined by ELISA, occurred approximately 4 hours (1.5 ng/mL) after intramuscular dosing and 7 hours (0.6 ng/mL) after subcutaneous dosing. Multiple dose subcutaneous pharmacokinetic studies were conducted in 38 healthy male subjects. There was no accumulation of ACTIMMUNE  after 12 consecutive daily injections of 100 mcg/m2. Pharmacokinetic studies in patients with Chronic Granulomatous Disease have not been performed.

Trace amounts of interferon-gamma were detected in the urine of squirrel monkeys following intravenous administration of 500 mcg/kg. Interferon-gamma was not detected in the urine of healthy human volunteers following administration of 100 mcg/m2 of ACTIMMUNE  by the intravenous, intramuscular and subcutaneous routes. In vitro  perfusion studies utilizing rabbit livers and kidneys demonstrate that these organs are capable of clearing interferon-gamma from perfusate. Studies of the administration of interferon-gamma to nephrectomized mice and squirrel monkeys demonstrate a reduction in clearance of interferon-gamma from blood; however, prior nephrectomy did not prevent elimination.

Effects in Chronic Granulomatous Disease

A randomized, double-blind, placebo-controlled study of ACTIMMUNE  (Interferon gamma-1b) in patients with Chronic Granulomatous Disease (CGD), was performed to determine whether ACTIMMUNE  administered subcutaneously on a three times weekly schedule could decrease the incidence of serious infectious episodes and improve existing infectious and inflammatory conditions in patients with Chronic Granulomatous Disease. One hundred twenty-eight eligible patients were enrolled on this study including patients with different patterns of inheritance. Most patients received prophylactic antibiotics. Patients ranged in age from 1 to 44 years with the mean age being 14.6 years. The study was terminated early following demonstration of a highly statistically significant benefit of ACTIMMUNE  therapy compared to placebo with respect to time to serious infection (p=0.0036), the primary endpoint of the investigation. Serious infection was defined as a clinical event requiring hospitalization and the use of parenteral antibiotics. The final analysis provided further support for the primary endpoint (p=0.0006). There was a 67 percent reduction in relative risk of serious infection in patients receiving ACTIMMUNE  (n=63) compared to placebo (n=65). Additional supportive evidence in the number of primary serious infections in the ACTIMMUNE  group (30 on placebo versus 14 on ACTIMMUNE, p=0.002) and the total number and rate of serious infections including recurrent events (56 on placebo versus 20 on ACTIMMUNE, p=<0.0001). Moreover, the length of hospitalization for the treatment of all clinical events provided evidence highly supportive of an ACTIMMUNE  treatment benefit. Placebo patients required three times as many inpatient hospitalization days for treatment of clinical events compared to patients receiving ACTIMMUNE  (1493 versus 497 total days, p=0.02). An ACTIMMUNE  treatment benefit with respect to time to serious infection was consistently demonstrated in all subgroup analyses according to stratification factors, including pattern of inheritance, use of prophylactic antibiotics, as well as age. There was a 67 percent reduction in relative risk of serious infection in patients receiving ACTIMMUNE  compared to placebo across all groups. The beneficial effect of ACTIMMUNE  therapy was observed throughout the entire study, in which the mean duration of ACTIMMUNE  administration was 8.9 months/patient.

Effects in Osteopetrosis

A controlled, randomized study in patients with severe, malignant osteopetrosis was conducted with ACTIMMUNE  administered subcutaneously three times weekly. Sixteen patients were randomized to receive either ACTIMMUNE  plus calcitriol (n=11), or calcitriol alone (n=5). Patients ranged in age from 1 month to 8 years, mean 1.5 years. Treatment failure was considered to be disease progression as defined by 1) death, 2) significant reduction in hemoglobin or platelet counts, 3) a serious bacterial infection requiring antibiotics, or 4) a 50 dB decrease in hearing or progressive optic atrophy. The median time to disease progression was significantly delayed in the ACTIMMUNE  plus calcitriol arm versus calcitriol alone. In the treatment arm, the median was not reached. Based on the observed data, however, the median time to progression in this arm was at least 165 days versus a median of 65 days in the calcitriol alone arm. In an analysis which combined data from a second study, 19 of 24 patients treated with ACTIMMUNE  plus or minus calcitriol for at least 6 months had reduced trabecular bone volume compared to baseline.


ACTIMMUNE  is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease.

ACTIMMUNE  is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis.


ACTIMMUNE  is contraindicated in patients who develop or have known hypersensitivity to interferon-gamma, E. coli  derived products, or any component of the product.


Cardiovascular Disorders

Acute and transient "flu-like" symptoms such as fever and chills induced by ACTIMMUNE  at doses of 250 mcg/m2/day (greater than 10 times the weekly recommended dose) or higher may exacerbate pre-existing cardiac conditions. ACTIMMUNE  should be used with caution in patients with pre-existing cardiac conditions, including ischemia, congestive heart failure or arrhythmia.

Neurologic Disorders

Decreased mental status, gait disturbance and dizziness have been observed, particularly in patients receiving ACTIMMUNE  doses greater than 250 mcg/m2/day (greater than 10 times the weekly recommended dose). Most of these abnormalities were mild and reversible within a few days upon dose reduction or discontinuation of therapy. Caution should be exercised when administering ACTIMMUNE  to patients with seizure disorders or compromised central nervous system function.

Bone Marrow Toxicity

Reversible neutropenia and thrombocytopenia that can be severe and may be dose related have been observed during ACTIMMUNE  therapy. Caution should be exercised when administering ACTIMMUNE  to patients with myelosuppression.

Hepatic Toxicity

Elevations of AST and/or ALT (up to 25-fold) have been observed during ACTIMMUNE  therapy. The incidence appeared to be higher in patients less than 1 year of age compared to older children. The transaminase elevations were reversible with reduction in dosage or interruption of ACTIMMUNE  treatment. Patients begun on ACTIMMUNE  before age one year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE  dosage should be modified (see DOSAGE AND ADMINISTRATIONDose Modification).



Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE. If such an acute reaction develops the drug should be discontinued immediately and appropriate medical therapy instituted. Transient cutaneous rashes have occurred in some patients following injection but have rarely necessitated treatment interruption.

Information for Patients

Patients being treated with ACTIMMUNE  and/or their parents should be informed regarding the potential benefits and risks associated with treatment. If home use is determined to be desirable by the physician, instructions on appropriate use should be given, including review of the contents of the Patient Information Insert. This information is intended to aid in the safe and effective use of the medication. It is not a disclosure of all possible adverse or intended effects.

If home use is prescribed, a puncture resistant container for the disposal of used syringes and needles should be supplied to the patient. Patients should be thoroughly instructed in the importance of proper disposal and cautioned against any reuse of needles and syringes. The full container should be disposed of according to the directions provided by the physician (see Patient Information Insert).

The most common adverse experiences occurring with ACTIMMUNE  therapy are "flu-like" or constitutional symptoms such as fever, headache, chills, myalgia or fatigue (see ADVERSE REACTIONS) which may decrease in severity as treatment continues. Some of the "flu-like" symptoms may be minimized by bedtime administration. Acetaminophen may be used to prevent or partially alleviate the fever and headache.

Laboratory Tests

In addition to those tests normally required for monitoring patients with Chronic Granulomatous Disease and osteopetrosis, the following laboratory tests are recommended for all patients on ACTIMMUNE  (Interferon gamma-1b) therapy prior to the beginning of and at three month intervals during treatment (see WARNINGS: Bone Marrow and Hepatic Toxicity).

  • Hematologic tests - including complete blood counts, differential and platelet counts
  • Blood chemistries - including renal and liver function tests. In patients less than 1 year of age, liver function tests should be measured monthly (see ADVERSE REACTIONS: Post-Marketing Experience).
  • Urinalysis

Drug Interactions

Interactions between ACTIMMUNE and other drugs have not been fully evaluated. Caution should be exercised when administering ACTIMMUNE  in combination with other potentially myelosuppressive agents (see WARNINGS).

Preclinical studies in rodents using species-specific interferon-gamma have demonstrated a decrease in hepatic microsomal cytochrome P-450 concentrations. This could potentially lead to a depression of the hepatic metabolism of certain drugs that utilize this degradative pathway.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Carcinogenesis: ACTIMMUNE  has not been tested for its carcinogenic potential.

Mutagenesis:  Ames tests using five different tester strains of bacteria with and without metabolic activation revealed no evidence of mutagenic potential. ACTIMMUNE  was tested in a micronucleus assay for its ability to induce chromosomal damage in bone marrow cells of mice following two intravenous doses of 20 mg/kg. No evidence of chromosomal damage was noted.

Impairment of Fertility:  Female cynomolgus monkeys treated with daily subcutaneous doses of 30 or 150 mcg/kg ACTIMMUNE  (approximately 20 and 100 times the human dose) exhibited irregular menstrual cycles or absence of cyclicity during treatment. Similar findings were not observed in animals treated with 3 mcg/kg ACTIMMUNE.

Female mice receiving recombinant murine IFN-gamma (rmulFN-gamma) at 32 times the maximum recommended clinical dose of ACTIMMUNE  for 4 weeks via intramuscular injection exhibited an increased incidence of atretic ovarian follicles.

Male cynomolgus monkeys treated intravenously for 4 weeks with 8 times the maximum recommended clinical dose of ACTIMMUNE  exhibited decreased spermatogenesis. The impact of this finding on fertility is not known. Male mice receiving rmulFN-gamma at 32 times the maximum recommended clinical dose of ACTIMMUNE  for 4 weeks via intramuscular injection exhibited decreased spermatogenesis.

Male mice treated subcutaneously with rmuIFN-gamma from shortly after birth through puberty, with 280 times the maximum recommended clinical dose of ACTIMMUNE  exhibited profound yet reversible decreases in sperm counts and fertility, and an increase in the number of abnormal sperm.

The clinical significance of these findings observed following treatment of mice with rmulFN-gamma is uncertain.


Teratogenic Effects:  Pregnancy Category C. ACTIMMUNE  has shown an increased incidence of abortions in primates when given in doses approximately 100 times the human dose. A study in pregnant primates treated with subcutaneous doses 2-100 times the human dose failed to demonstrate teratogenic activity for ACTIMMUNE.

Female mice treated subcutaneously with rmulFN-gamma at 280 times the maximum recommended clinical dose of ACTIMMUNE  from shortly after birth through puberty but not during pregnancy had offspring which exhibited decreased body weight during the lactation period. The clinical significance of this finding observed following treatment of mice with rmulFN-gamma is uncertain.

There are no adequate and well-controlled studies in pregnant women. ACTIMMUNE  should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether ACTIMMUNE  is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ACTIMMUNE, a decision should be made whether to discontinue nursing or to discontinue the drug, dependent upon the importance of the drug to the mother.


The following data on adverse reactions are based on the subcutaneous administration of ACTIMMUNE  at a dose of 50 mcg/m2, three times weekly, in patients with Chronic Granulomatous Disease (CGD) during an investigational trial in the United States and Europe.

The most common adverse events observed in patients with CGD are shown in the following table:

Percent of Patients
Clinical Toxicity ACTIMMUNE CGD (n=63) Placebo CGD (n=65)
Fever 52 28
Headache 33 9
Rash 17 6
Chills 14 0
Injection site erythema or tenderness 14 2
Fatigue 14 11
Diarrhea 14 12
Vomiting 13 5
Nausea 10 2
Myalgia 6 0
Arthralgia 2 0
Injection site pain 0 2

Miscellaneous adverse events which occurred infrequently in patients with CGD and may have been related to underlying disease included back pain (2 percent versus 0 percent), abdominal pain (8 percent versus 3 percent) and depression (3 percent versus 0 percent) for ACTIMMUNE  and placebo treated patients, respectively.

Similar safety data were observed in 34 patients with severe malignant osteopetrosis.

ACTIMMUNE  has also been evaluated in additional disease states in studies in which patients have generally received higher doses (>100 mcg/m2/three times weekly) administered by intramuscular or subcutaneous injection, or intravenous infusion. All of the previously described adverse reactions which occurred in patients with Chronic Granulomatous Disease have also been observed in patients receiving higher doses. Adverse reactions not observed in patients with Chronic Granulomatous Disease but reported in patients receiving ACTIMMUNE  (Interferon gamma-1b) in other studies include: Cardiovascular—hypotension, syncope, tachyarrhythmia, heart block, heart failure, and myocardial infarction. Central Nervous System—confusion, disorientation, gait disturbance, Parkinsonian symptoms, seizure, hallucinations, and transient ischemic attacks. Gastrointestinal—dyspepsia, hepatic insufficiency, gastrointestinal bleeding, and pancreatitis, including pancreatitis with fatal outcome. General Disorders and Administration Site Conditions—malaise, injection site hemorrhage. Hematologic—deep venous thrombosis and pulmonary embolism. Immunological—increased autoantibodies, lupus-like syndrome. Metabolic—hyponatremia, hyperglycemia and hypertriglyceridemia. Musculoskeletal—clubbing, muscle spasms. Pulmonary—tachypnea, bronchospasm, and interstitial pneumonitis. Renal—reversible renal insufficiency. Other—chest discomfort, exacerbation of dermatomyositis.

Abnormal Laboratory Test Values:  Elevations of ALT and AST, neutropenia, thrombocytopenia, and proteinuria have been observed (see WARNINGS and PRECAUTIONSLaboratory Tests).

No neutralizing antibodies to ACTIMMUNE  have been detected in any Chronic Granulomatous Disease patients receiving ACTIMMUNE.

Post-Marketing Experience

Children with CGD less than 3 years of age:
Data on the safety and activity of ACTIMMUNE  in 37 patients under the age of 3 years was pooled from four uncontrolled post-marketing studies. The rate of serious infections per patient-year in this uncontrolled group was similar to the rate observed in the ACTIMMUNE  treatment groups in controlled trials. Developmental parameters (height, weight and endocrine maturation) for this uncontrolled group conformed to national normative scales before and during ACTIMMUNE  therapy.

In 6 of the 10 patients receiving ACTIMMUNE  therapy before age one year 2-fold to 25-fold elevations from baseline of AST and/or ALT were observed. These elevations occurred as early as 7 days after starting treatment. Treatment with ACTIMMUNE  was interrupted in all 6 of these patients and was restarted at a reduced dosage in 4. Liver transaminase values returned to baseline in all patients and transaminase elevation recurred in one patient upon ACTIMMUNE  rechallenge. An 11-fold alkaline phosphatase elevation and hypokalemia in one patient and neutropenia (ANC=525 cells/mm3) in another patient resolved with interruption of ACTIMMUNE  treatment and did not recur with rechallenge.

In the post-marketing safety database clinically significant adverse events observed during ACTIMMUNE  therapy in children under the age of three years (n=14) included: two cases of hepatomegaly, and one case each of Stevens-Johnson syndrome, granulomatous colitis, urticaria, and atopic dermatitis.


Central nervous system adverse reactions including decreased mental status, gait disturbance and dizziness have been observed, particularly in cancer patients receiving doses greater than 100 mcg/m2/day by intravenous or intramuscular administration. These abnormalities were reversible within a few days upon dose reduction or discontinuation of therapy. Reversible neutropenia, elevation of hepatic enzymes and of triglycerides, and thrombocytopenia have also been observed.


The recommended dosage of ACTIMMUNE  for the treatment of patients with Chronic Granulomatous Disease and severe, malignant osteopetrosis is 50 mcg/m2 (1 million IU/m2) for patients whose body surface area is greater than 0.5 m2 and 1.5 mcg/kg/dose for patients whose body surface area is equal to or less than 0.5 m2. Note that the above activity is expressed in International Units (1 million IU/50mcg). This is equivalent to what was previously expressed as units (1.5 million U/50mcg). Injections should be administered subcutaneously three times weekly (for example, Monday, Wednesday, Friday). The optimum sites of injection are the right and left deltoid and anterior thigh. ACTIMMUNE  can be administered by a physician, nurse, family member or patient when trained in the administration of subcutaneous injections. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

The formulation does not contain a preservative. A vial of ACTIMMUNE  is suitable for a single use only. The unused portion of any vial should be discarded. Higher doses are not recommended. Safety and efficacy has not been established for ACTIMMUNE  given in doses greater or less than the recommended dose of 50 mcg/m2. The minimum effective dose of ACTIMMUNE  has not been established.

ACTIMMUNE  should not be mixed with other drugs in the same syringe.

Dose Modification

If severe reactions occur, the dosage should be reduced by 50 percent or therapy should be interrupted until the adverse reaction abates.

ACTIMMUNE  may be administered using either sterilized glass or plastic disposable syringes.


ACTIMMUNE  (Interferon gamma-1b) is a sterile, clear, colorless solution filled in a single-use vial for subcutaneous injection. Each 0.5 mL of ACTIMMUNE  contains: 100 mcg (2 million IU) of Interferon gamma-1b, formulated in 20 mg mannitol, 0.36 mg sodium succinate, 0.05 mg polysorbate 20 and Sterile Water for Injection.

Single vial (NDC 64116-011-01)
Cartons of 12 (NDC 64116-011-12)

Stability and Storage

Vials of ACTIMMUNE  must be placed in a 2-8°C (36-46°F) refrigerator immediately upon receipt to ensure optimal retention of physical and biochemical integrity. DO NOT FREEZE. Avoid excessive or vigorous agitation. DO NOT SHAKE. An unentered vial of ACTIMMUNE  should not be left at room temperature for a total time exceeding 12 hours prior to use. Vials exceeding this time period should not be returned to the refrigerator; such vials should be discarded.

Do not use beyond the expiration date stamped on the vial.


  1. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324 : 509-516, 1991.
  2. Beard CJ, Key L, Newburger PE, Ezekowitz RAB, et al.  Neutrophil defect associated with malignant infantile osteopetrosis. J Lab Clin Med 108 : 498-505, 1986.
  3. Shankar L, Gerritsen EJA, and Key LL. Osteopetrosis: pathogenesis and rationale for the use of interferon-γ-1b. Biodrugs : 23-29, 1997.
  4. Key LL, Rodriguiz RM, Willi SM. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 24 : 1594-1599, 1995.

Manufactured by:
InterMune, Inc.
Brisbane, CA 94005
U.S. License No. 1626
Revised January 2009
©2009 InterMune, Inc.                           PH01037.04

Information for the Patient/Caregiver

ACTIMMUNE® (Interferon gamma-1b)


ACTIMMUNE  is supplied in single-use vials. The unused portion of each vial should be disposed of as instructed by your physician. DO NOT SHAKE.

Your physician will tell you what size needle and syringe to use and also give you instructions on sterile technique. Keep all used syringes and needles out of the reach of children. Follow your physician’s instructions on the safe disposal of used syringes and needles.


In measuring the correct dose for injection, be sure to check that the ACTIMMUNE®  solution is clear. If the solution is cloudy or hazy, do not inject it, but return the ACTIMMUNE  vial to your pharmacist or prescribing physician.

1.  Wash your hands thoroughly with soap and water before preparing the medication. This helps prevent infection.

image of proper handwashing technique

2.  Check the date on the ACTIMMUNE  vial to be sure the drug has not expired.

image of where the solutions lot number and expiration date can be
								found on the bottle

3.  Remove the protective plastic cap and wipe the rubber stopper located on top of the ACTIMMUNE®  vial with an alcohol swab.

image of where on the stopper of the vial the alcohol swab should
								be applied

4.  Draw air into the syringe by pulling back on the plunger. The amount of air should be equal to the ACTIMMUNE  dose.

image of drawing air into the syringe

5.  Remove and save the needle guard. Slowly insert the needle straight through the center of the rubber stopper into the ACTIMMUNE  vial.

image of the syringe properly inserted into the vial

6.  Gently push the plunger to discharge the air into the vial.

image of the proper discharge of air in the syringe into the vial

7.  Turn the vial upside down with the syringe needle still in it and hold it in one hand. Be sure the tip of the needle is in the solution. Using your other hand slowly pull back on the plunger in a continuous motion until the correct amount of ACTIMMUNE®  solution is in the syringe.

image of of the proper draw of solution from the vial into the

8.  Remove the needle from the ACTIMMUNE  vial and replace the needle guard until time of administration or injection. Administration should be as soon after filling the syringe as possible; do not store ACTIMMUNE  in the syringe.

image of the proper application of the needle guard


Your doctor or nurse will teach you how to locate appropriate injection sites. It is very important that you rotate the site of an injection each time you give the medication. Even if you or your child develop a preference for one site—as often happens—you still should rotate the injection site.

Following are the injection sites most often recommended:

■   Upper Arm

image of the proper injection site-arm

■   Abdomen

image of the proper injection site-abdomen

■   Thigh

image of the proper injection site-thigh


Your doctor or nurse will provide you with hands-on training on how to give an injection. Needles and syringes should be used only once to ensure sterility of both the needle and the syringe. The following is a review of the steps involved in giving the medication:

1.  Cleanse the injection site with an alcohol-saturated cotton ball or cotton swab.

image of proper swabing of injection site

2.  Remove the needle guard from the syringe filled with the proper dose of solution and hold the syringe the way you would hold a pencil. Double check that the correct amount of ACTIMMUNE®  solution is in the syringe.

image of proper hold of the syringe the way you would hold a

3.  Squeeze the skin between your fingers before and during the injection. Insert the needle into the skin at a 45° angle with a quick, firm motion. This hurts less than pushing the needle in slowly.

image of fingers squeezing the injection site between your fingers
								before and during the injection

4.  After the needle is in, pull back very slightly with one hand on the plunger to see if blood comes into the syringe. This is to be sure that the needle has not entered a blood vessel. If blood does come into the syringe, do not inject the ACTIMMUNE®  solution. Withdraw the needle and insert at another location.

5.  If blood does not come into the syringe, slowly (within a few seconds) inject the solution by gently pushing the plunger until the syringe is empty.

image of the solution being injected into the injection site

6.  Withdraw the needle quickly, pulling it straight out, and apply pressure over the injection site with a dry gauze pad or cotton ball. A drop of blood may appear. Put a Band-Aid® on the injection site if desired.

image of applied pressure over the injection site with a dry gauze
								pad or cotton ball

7.  To prevent injury, safely dispose of all used needles and syringes after a single use as instructed by your physician by following these simple steps:

Place all used needles and syringes in a hard, plastic container with a screw-on cap, or a metal container with a plastic lid, such as a coffee can properly labeled as to content. If a metal container is used, cut a small hole in the plastic lid and tape the lid to the metal container. When the metal container is full, cover the hole with tape and throw it away. If a hard, plastic container is used, always screw the cap on tightly after each use. When the plastic container is full, tape around the cap and throw it away.
Do not use glass or clear, plastic containers, or any container that will be recycled or returned to a store.
Always store the container out of the reach of children.
Please check with your doctor, nurse or pharmacist for other suggestions. There may be special state and local laws that they will discuss with you.
image of proper disposal of used syringe

8.  Occasionally a problem may develop at the injection site. If you notice any of the following signs or symptoms, contact your doctor or nurse:

A lump or swelling that doesn’t go away
Bruising that doesn’t go away
Any signs of infection or inflammation at an injection site (pus, persistent redness, surrounding skin that is hot to the touch, persistent pain after the injection)


ACTIMMUNE®  (Interferon gamma-1b) must be refrigerated immediately. Refrigerate at 36° to 46° Fahrenheit (2° to 8° Centigrade). DO NOT FREEZE.

ACTIMMUNE  is supplied in single-use vials. The unused portion of each vial should be disposed of according to state and local regulations as instructed by your physician. If you have any questions, contact your physician.

InterMune, Inc.
Brisbane, CA 94005
November 2006


NDC 64116-011-01

(Interferon gamma-1b)

100 mcg (2 million IU)/0.5 mL
0.5 mL Single-use vial

US License No.: 1626
Manufactured by:
Intermune, Inc.
Brisbane, CA 94005

See package insert.
Refrigerate at
2° to 8°C/
36° to 46°F.

image of vial label



NDC 64116-011-12

(Interferon gamma-1b)

How supplied: Each carton contains 12 single-use
vials of Interferon gamma-1b, ACTIMMUNE.

Contents: Each 0.5 mL vial of ACTIMMUNE
contains 100 mcg (2 million IU) Interferon
gamma-1b formulated in 20 mg mannitol, 0.36 mg
sodium succinate, 0.05 mg polysorbate 20 and
Sterile Water for Injection for subcutaneous
injection. ACTIMMUNE  contains no preservatives.

Dosage and administration: See
package insert for full prescribing
information. ACTIMMUNE  is
suitable for single-use only.

Storage: Refrigerate at
2° to 8°C/36° to 46°F.

(Interferon gamma-1b)

Manufactured by:
Intermune, Inc.
Brisbane, CA 94005
US License No.: 1626



(Interferon gamma-1b)

Dispensing pharmacist:
1. Refrigerate
    (2° to 8°C/36° to 46°F).
2. Be sure patient information
    is enclosed.
3. Remove physician insert
    before dispensing.




image of carton label

interferon gamma-1b injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:64116-011
Route of Administration SUBCUTANEOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Interferon gamma-1b (Interferon gamma-1b) Interferon gamma-1b 100 ug  in 0.5 mL
Inactive Ingredients
Ingredient Name Strength
mannitol 20 mg  in 0.5 mL
sodium succinate 0.36 mg  in 0.5 mL
polysorbate 20 0.05 mg  in 0.5 mL
Product Characteristics
Color      Score     
Shape Size
Flavor Imprint Code
# Item Code Package Description Multilevel Packaging
1 NDC:64116-011-12 12 VIAL, SINGLE-USE ( VIAL) in 1 CARTON contains a VIAL, SINGLE-USE (64116-011-01)
1 NDC:64116-011-01 0.5 mL in 1 VIAL, SINGLE-USE This package is contained within the CARTON (64116-011-12)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA103836 02/25/1999

Labeler - InterMune, Inc. (035491294)
Registrant - InterMune, Inc. (035491294)
Name Address ID/FEI Operations
Boehringer Ingelheim Pharma GmbH & Co KG 340700520 MANUFACTURE

Revised: 04/2011 InterMune, Inc.

Reproduced with permission of U.S. National Library of Medicine

Copyright © 2020 by Dionisios Fentas || Terms of Use


Prescription Marketed Drugs Alphabetically
A| B| C| D| E| F| G| H| I| J| K| L| M| N| O| P| Q| R| S| T| U| V| W| X| Y| Z| 0-9

Prescription(RX) Drugs
Over-the-counter (OTC) Drugs
Homeopathic Drugs
Animal Drugs